Boeh Ing Abandons Cerestat Trial
Boehringer Ingelheim and Cambridge NeuroScience have said that theywill terminate a Phase III trial of Cerestat (aptiganel), for the treatment of stroke, following a second interim analysis of results from 628 patients who were enrolled in the trial before the companies decided to call a temporary halt to the accrual of new patients earlier this year (Marketletter June 30).
Still No Verdict The companies say that "the plan is now to further evaluate the data before making any decisions about the future development of Cerestat."
In September, it was reported that Cambridge NeuroScience had also stopped its Phase III trial of Cerestat in traumatic brain injury patients because a planned interim analysis of the data showed insufficient evidence of a positive clinical impact (Marketletter September 29). The company says that it is still collecting data from this latter trial, and is committed to "fully assessing the effects of the drug" once the database is complete.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze